• Home
  • About
    • Psilocybin (Magic Mushrooms)
    • Ayahuasca (Chacruna – Kaapi – Yajé)
    • MDMA (MDA – Sassafras)
    • Peyote Mescaline (Huachuma)
    • Kambo – Amazonian Frog
    • 5-MeO-DMT (Toad Medicine)
    • Rapé And Sacred Tobacco
    • Iboga (Ibogaine)
    • LSD (Lysergic Acid Diethylamide)
    • Cannabis (Marijuana)
    • Ketamine
    • Psychedelic Integration
    • Psychedelics Advocates
    • Frequently Asked Questions
    • Mental Health Symptoms
    • Substances Test Kits
    • Manifesto
    • Research Internship
  • Treatments
    • Latest Psychedelic Research
    • Addiction
    • Alcoholism
    • Anxiety
    • Bipolar Disorder
    • Cancer
    • Cluster Headaches
    • Depression
    • End Of Life
    • OCD
    • Neuropathy
    • Pain
    • Parkinson’s Disease
    • PTSD
    • Smoking
    • Help Treat Mental Illness
  • Microdosing
    • What is Microdosing?
    • Microdosing Magic Mushrooms
    • Microdosing LSD
    • Microdosing MDMA
    • Microdosing Ayahuasca
    • Microdosing Mescaline
    • Microdosing Cannabis
    • Microdosing Ibogaine
  • Resources
    • Past Events
    • ALL Locations
    • Ketamine Treatment
    • Medical Trials And Research
    • Psychedelic Research
    • EntheoPodcasts
    • In The News
    • Books On Psychedelics
    • Related Videos
    • EntheoResources
    • Terence McKenna
    • What Is Psychedelic Art?
    • Useful Links
    • Movies & Documentaries
    • Michael Pollan
Contact
  • Follow
  • Follow
  • Follow
  • Follow

New Tools for Depression

by SpiSafConf | Aug 12, 2022 | Bipolar Disorder, Chronic Pain, Kambo, LSD, MDMA Sassafras Molly, Microdosing, NN-Dimethyltryptamine, OCD, Psilocybin Magic Mushroom, Psychedelic Medicine

COULD AN OVERACTIVE IMMUNE SYSTEM make you depressed? In the late 1990s, psychiatrist Andrew Miller and his colleagues began to notice that patients with cancer, cardiovascular disease, obesity and Crohn’s disease—all conditions that cause higher than normal levels of...

IMPORTANT NOTICE:

This community is being designed as a secure space. It is not a place to seek, encourage, or participate in the procurement of controlled substances. Do not bring, buy, sell, transfer, or arrive on any illegal substances, or swap information on how to buy them. Attendees and/or members of this community who violate these basic house rules will be removed from the community and will not be allowed to attend future events.

Psychedelic Research

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity.

Aug 17, 2022

Marked increases in positive mood were produced by MDMA. Decreased CBF only was observed after MDMA, and this was localized to the right medial temporal lobe (MTL), thalamus, inferior visual cortex, and the somatosensory cortex. Decreased CBF in the right amygdala and...

The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favorite and worst autobiographical memories

Aug 17, 2022

Favorite memories were rated as significantly more vivid, emotionally intense and positive after MDMA than placebo and worst memories were rated as less negative. Functional MRI data from 17 participants showed robust activations to AMs in regions known to be involved...

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after MDMA psychotherapy: a prospective longterm follow-up study

Aug 17, 2022

Results for the 16 CAPS completers showed there were no statistical differences between mean CAPS score at LTFU (mean = 23.7; SD = 22.8) (tmatched = 0.1; df = 15, p = 0.91) and the mean CAPS score previously obtained at Study Exit (mean = 24.6, SD = 18.6). On average,...

MDMA-assisted psychotherapy for posttraumatic stress disorder in military veterans, firefighters, and police officers: a randomized, double-blind, dose-response, phase 2 clinical trial

Aug 17, 2022

Between Nov 10, 2010, and Jan 29, 2015, 26 veterans and first responders met eligibility criteria and were randomly assigned to receive 30 mg (n=7), 75 mg (n=7), or 125 mg (n=12) of MDMA plus psychotherapy. At the primary endpoint, the 75 mg and 125 mg groups had...

A randomized, controlled pilot study of MDMA-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)

Aug 17, 2022

We found that MDMA-assisted psychotherapy can be safely administered in a clinical setting. No drug-related serious adverse events occurred. We did not see statistically significant reductions in CAPS scores (p = 0.066), although there was clinically and statistically...

Psychedelic Medicine

LSD modulates music-induced imagery via changes in Para hippocampal connectivity

Aug 16, 2022

Results revealed increased PHC-visual cortex (VC) functional connectivity and PHC to VC information flow in the interaction between music and LSD. This latter result correlated positively with ratings of enhanced eyes-closed visual imagery, including imagery of an...

New Tools for Depression

Aug 12, 2022

COULD AN OVERACTIVE IMMUNE SYSTEM make you depressed? In the late 1990s, psychiatrist Andrew Miller and his colleagues began to notice that patients with cancer, cardiovascular disease, obesity and Crohn’s disease—all conditions that cause higher than normal levels of...

A Trip to Therapy

Aug 12, 2022

THE EXAMINATION ROOMS IN THE BLUESTON CENTER FOR CLINICAL RESEARCH at the New York University College of Dentistry are exactly what you might expect of a facility that conducts trials of dental and medical therapies. There are reclining exam chairs, linoleum floors,...

Psychedelic Research in 2022

Aug 12, 2022

During his decades as Massachusetts General Hospital’s Chief of Psychiatry, Jerry Rosenbaum observed that patients suffering from a range of mental illnesses would sometimes get stuck in a state of rumination, or unceasing cycles of unpleasant, self-deprecating...

More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression

Aug 11, 2022

Patients showed a significant pessimism bias at baseline [t(14) = -3.260, p = 0.006; 95% CI (-0.16, -0.03), g = 1.1] which was related to the severity of their depressive symptoms (rs = -0.55, p = 0.017). One week after psilocybin treatment, this bias was...

© 2023| All Rights Reserved, EntheoMedicine Community
  • Follow
  • Follow
  • Follow
  • Follow